Genetic link between cancer and thrombosis

Journal of Clinical Oncology

Volumn 27, Issue 29, 2009, Pages 4827-4833

  Boccaccio, Carla ^a   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BLOOD CLOTTING FACTOR 7A; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTEIN KINASE C; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; SCATTER FACTOR; THROMBOPLASTIN; VASCULOTROPIN; VITRONECTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; BLOOD CLOTTING; CANCER CELL; CANCER GROWTH; CANCER INVASION; COX 2 GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC LINKAGE; HEMOSTASIS; HUMAN; MALIGNANT TRANSFORMATION; MICROENVIRONMENT; NONHUMAN; ONCOGENE; ONCOGENE MET; ONCOGENE RAS; P53 GENE; PAI 1 GENE; PRIORITY JOURNAL; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; SYNDROME; THROMBOSIS; TROUSSEAU SYNDROME; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MORTALITY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HEMOSTASIS; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS; THROMBOSIS;

EID: 70350731332     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7199     Document Type: Review

References (79)

1. Trousseau A: Phlegmasia alba dolens, in Trousseau A (ed): Clinique Médicale de l'Hotel-Dieu de Paris. Paris, France, JB Balliè re et Fils, 1865, pp 654-712
2. Sack GH Jr, Levin J, Bell WR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56:1-37, 1977
3. Khorana AA, Rao MV: Approaches to riskstratifying cancer patients for venous thromboembolism. Thromb Res 120:S41-S50, 2007 (suppl 2)
4. Falanga A, Barbui T, Rickles FR: Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 34: 204-210, 2008
5. Varki A: Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood 110:1723-1729, 2007
6. Prandoni P, Lensing AW, Buller HR, et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133, 1992
7. Baron JA, Gridley G, Weiderpass E, et al: Venous thromboembolism and cancer. Lancet 351: 1077-1080, 1998
8. Sorensen HT, Mellemkjaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173, 1998
9. Rickles FR, Levine MN: Epidemiology of thrombosis in cancer. Acta Haematol 106:6-12, 2001
10. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 6:401-410, 2005
11. Prandoni P, Piccioli A: Thrombosis as a harbinger of cancer. Curr Opin Hematol 13:362-365, 2006
12. Sorensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000
13. Trujillo-Santos J, Prandoni P, Rivron-Guillot K, et al: Clinical outcome in patients with venous thromboembolism and hidden cancer: Findings from the RIETE Registry. J Thromb Haemost 6:251-255, 2008
14. Piccioli A, Lensing AW, Prins MH, et al: Extensive screening for occult malignant disease in idiopathic venous thromboembolism: A prospective randomized clinical trial. J Thromb Haemost 2:884-889, 2004
15. Buller HR, van Doormaal FF, van Sluis GL, et al: Cancer and thrombosis: From molecular mechanisms to clinical presentations. J Thromb Haemost 5:246-254, 2007 (suppl 1)
16. Sorensen HT, Johnsen SP: Venous thromboembolism and subsequent short-term risk of an occult cancer. J Thromb Haemost 6:249-250, 2008
17. Dvorak HF, Rickles FR: Malignacy and hemostasis, in Colman RW (ed): Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Philadelphia, PA, Lippincott Williams & Wilkins, 2005, pp 851-873
18. Rickles FR: Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 35:103-110, 2006
19. Zwicker JI, Furie BC, Furie B: Cancerassociated thrombosis. Crit Rev Oncol Hematol 62:126-136, 2007
20. Wu KK, Thiagarajan P: Role of endothelium in thrombosis and hemostasis. Annu Rev Med 47:315-331, 1996
21. Smith WL, De Witt DL, Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182, 2000
22. Mann KG: Biochemistry and physiology of blood coagulation. Thromb Haemost 82:165-174, 1999
23. Dahlback B: Blood coagulation. Lancet 355: 1627-1632, 2000
24. Collen D: The plasminogen (fibrinolytic) system. Thromb Haemost 82:259-270, 1999
25. Rak J, Milsom C, Yu J: Tissue factor in cancer. Curr Opin Hematol 15:522-528, 2008
26. Tesselaar ME, Romijn FP, van der Linden IK, et al: Microparticle- associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost 5:520-527, 2007
27. Zwicker JI: Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 34:195-198, 2008
28. Rong Y, Post DE, Pieper RO, et al: PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65:1406-1413, 2005
29. Yu JL, May L, Lhotak V, et al: Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 105:1734-1741, 2005
30. Boccaccio C, Comoglio PM: Oncogenes, cancer and thrombosis, in Khorana AA (ed): Cancerassociated thrombosis. New York, NY, Informa Healthcare, 2007, pp 1-15
31. Denko NC, Giaccia AJ: Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 61:795-798, 2001
32. Tallman MS, Lefebvre P, Baine RM, et al: Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2:1341-1350, 2004
33. Birchmeier C, Birchmeier W, Gherardi E, et al: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925, 2003
34. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516, 2008
35. Trusolino L, Comoglio PM: Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nat Rev Cancer 2:289-300, 2002
36. Pennacchietti S, Michieli P, Galluzzo M, et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361, 2003
37. Boccaccio C, Sabatino G, Medico E, et al: The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434:396-400, 2005
38. Rak J, Yu JL, Luyendyk J, et al: Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66:10643-10646, 2006
39. Erickson LA, Fici GJ, Lund JE, et al: Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346:74-76, 1990
40. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792-1801, 2000
41. Trusolino L, Pugliese L, Comoglio PM: Interactions between scatter factors and their receptors: Hints for therapeutic applications. FASEB J 12:1267-1280, 1998
42. Dvorak HF: Tumors: Wounds that do not heal. N Engl J Med 315:1650-1659, 1986
43. Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost 3:1894-1904, 2005
44. Thiagarajan P, Rippon AJ, Farrell DH: Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry 35:4169-4175, 1996
45. Fernandez PM, Patierno SR, Rickles FR: Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 30:31-44, 2004
46. Bach TL, Barsigian C, Yaen CH, et al: Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 273:30719-30728, 1998
47. Palumbo JS, Kombrinck KW, Drew AF, et al: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302-3309, 2000
48. Palumbo JS, Potter JM, Kaplan LS, et al: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62:6966-6972, 2002
49. Palumbo JS, Barney KA, Blevins EA, et al: Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 6:812-819, 2008
50. Palumbo JS, Talmage KE, Massari JV, et al: Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110:133-141, 2007
51. Palumbo JS: Mechanisms linking tumor cellassociated procoagulant function to tumor dissemination. Semin Thromb Hemost 34:154-160, 2008
52. Versteeg HH, Ruf W: Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 32:24-32, 2006
53. Coughlin SR: Thrombin signalling and proteaseactivated receptors. Nature 407:258-264, 2000
54. Ruf W, Mueller BM: Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32:61-68, 2006 (suppl 1)
55. Belting M, Dorrell MI, Sandgren S, et al: Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10:502-509, 2004
56. Schaffner F, Ruf W: Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 34:147-153, 2008
57. Shi X, Gangadharan B, Brass LF, et al: Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2:395-402, 2004
58. Radjabi AR, Sawada K, Jagadeeswaran S, et al: Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem 283: 2822-2834, 2008
59. Nierodzik ML, Karpatkin S: Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355-362, 2006
60. Hu L, Lee M, Campbell W: Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104:2746-2751, 2004
61. McMahon B, Kwaan HC: The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 36:184-194, 2008
62. Bajou K, Noel A, Gerard RD, et al: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4:923-928, 1998
63. Bajou K, Maillard C, Jost M: Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23:6986-6990, 2004
64. McMahon GA, Peticlerc E, Stefansson S, et al: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276:33964-33968, 2001
65. Czekay RP, Aertgeerts K, Curriden SA, et al: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160:781-791, 2003
66. Stefansson S, Lawrence DA: Old dogs and new tricks: Proteases, inhibitors, and cell migration. Sci STKE 2003:e24, 2003
67. Lademann UA, Romer MU: Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost 100:1041-1046, 2008
68. Schneider DJ, Chen Y, Sobel BE: The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 100:1037-1040, 2008
69. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996
70. Daniel TO, Liu H, Morrow JD, et al: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574-4577, 1999
71. Cha YI, DuBois RN: NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med 58:239-252, 2007
72. Fulton AM, Ma X, Kundu N: Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 66:9794-9797, 2006
73. Sonoshita M, Takaku K, Sasaki N, et al: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta 716) knockout mice. Nat Med: 7:1048-1051, 2001
74. Lee AY: The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thromb Res 120:S121-S127, 2007 (suppl 2)
75. Petralia GA, Lemoine NR, Kakkar AK: Mechanisms of disease: The impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2:356-363, 2005
76. Milsom C, Anderson GM, Weitz JI, et al: Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 5:2550-2552, 2007
77. Huang EH, Wicha MS: Colon cancer stem cells: Implications for prevention and therapy. Trends Mol Med 14:503-509, 2008
78. Kakarala M, Wicha MS: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813-2820, 2008
79. Yang ZJ, Wechsler-Reya RJ: Hit 'em where they live: Targeting the cancer stem cell niche. Cancer Cell 11:3-5, 2007